Search hospitals > Arizona > Phoenix
Banner - University Medical Center Phoenix
Claim this profilePhoenix, Arizona 85006
Global Leader in Atrial Fibrillation
Global Leader in Congenital Aortic Stenosis
Conducts research for Heart Failure
Conducts research for Aortic Stenosis
Conducts research for Parotid Gland Cancer
204 reported clinical trials
25 medical researchers
Summary
Banner - University Medical Center Phoenix is a medical facility located in Phoenix, Arizona. This center is recognized for care of Atrial Fibrillation, Congenital Aortic Stenosis, Heart Failure, Aortic Stenosis, Parotid Gland Cancer and other specialties. Banner - University Medical Center Phoenix is involved with conducting 204 clinical trials across 367 conditions. There are 25 research doctors associated with this hospital, such as Michael Morris, MD, Jiaxin Niu, MD, Shakeela Bahadur, and Marvin Eng, MD.Top PIs
Michael Morris, MDMemorial Sloan Kettering Cancer Center2 years of reported clinical research
Studies Prostate Cancer
Studies Prostatic Neoplasm
13 reported clinical trials
19 drugs studied
Jiaxin Niu, MDBanner MD Anderson Cancer Center7 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
11 reported clinical trials
18 drugs studied
Shakeela BahadurBanner MD Anderson Cancer Center5 years of reported clinical research
Expert in Breast Cancer
Studies Parotid Gland Cancer
11 reported clinical trials
29 drugs studied
Marvin Eng, MDHenry Ford Hospital6 years of reported clinical research
Studies Mitral Regurgitation
Studies Mitral Valve Regurgitation
7 reported clinical trials
14 drugs studied
Clinical Trials running at Banner - University Medical Center Phoenix
Breast Cancer
Heart Failure
Cardiovascular Disease
Lung Cancer
Stroke
Mitral Regurgitation
Mitral Valve Regurgitation
Non-Small Cell Lung Cancer
Congestive Heart Failure
Sleep Apnea
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Banner - University Medical Center Phoenix?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.